Hoshi, S.; Yaginuma, K.; Meguro, S.; Onagi, A.; Matsuoka, K.; Hata, J.; Sato, Y.; Akaihata, H.; Kataoka, M.; Ogawa, S.;
et al. PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues. Curr. Oncol. 2023, 30, 7286-7302.
https://doi.org/10.3390/curroncol30080529
AMA Style
Hoshi S, Yaginuma K, Meguro S, Onagi A, Matsuoka K, Hata J, Sato Y, Akaihata H, Kataoka M, Ogawa S,
et al. PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues. Current Oncology. 2023; 30(8):7286-7302.
https://doi.org/10.3390/curroncol30080529
Chicago/Turabian Style
Hoshi, Seiji, Kei Yaginuma, Satoru Meguro, Akifumi Onagi, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa,
and et al. 2023. "PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues" Current Oncology 30, no. 8: 7286-7302.
https://doi.org/10.3390/curroncol30080529
APA Style
Hoshi, S., Yaginuma, K., Meguro, S., Onagi, A., Matsuoka, K., Hata, J., Sato, Y., Akaihata, H., Kataoka, M., Ogawa, S., Uemura, M., & Kojima, Y.
(2023). PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues. Current Oncology, 30(8), 7286-7302.
https://doi.org/10.3390/curroncol30080529
